These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 26399602)

  • 21. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
    Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
    Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.
    Choo R; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw DA; Cheung P; Pearse M
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):983-9. PubMed ID: 19409726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.
    Stephenson AJ; Scardino PT; Kattan MW; Pisansky TM; Slawin KM; Klein EA; Anscher MS; Michalski JM; Sandler HM; Lin DW; Forman JD; Zelefsky MJ; Kestin LL; Roehrborn CG; Catton CN; DeWeese TL; Liauw SL; Valicenti RK; Kuban DA; Pollack A
    J Clin Oncol; 2007 May; 25(15):2035-41. PubMed ID: 17513807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival.
    Bartkowiak D; Thamm R; Bottke D; Siegmann A; Böhmer D; Budach V; Wiegel T
    Acta Oncol; 2018 Mar; 57(3):362-367. PubMed ID: 28816074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.
    Ramey SJ; Agrawal S; Abramowitz MC; Moghanaki D; Pisansky TM; Efstathiou JA; Michalski JM; Spratt DE; Hearn JWD; Koontz BF; Liauw SL; Pollack A; Anscher MS; Den RB; Stephans KL; Zietman AL; Lee WR; Stephenson AJ; Tendulkar RD
    Eur Urol; 2018 Jul; 74(1):99-106. PubMed ID: 29128208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy : Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression.
    Lohm G; Neumann K; Budach V; Wiegel T; Hoecht S; Gollrad J
    Strahlenther Onkol; 2018 Apr; 194(4):325-332. PubMed ID: 29255924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
    Oehus AK; Kroeze SGC; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M; Christiansen H; Henkenberens C
    BMC Cancer; 2020 Apr; 20(1):362. PubMed ID: 32349700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of positive surgical margins on salvage radiation or androgen deprivation therapy following radical prostatectomy - a nationwide study.
    Stroomberg HV; Friberg AS; Helgstrand JT; Brasso K; Røder MA
    Acta Oncol; 2021 May; 60(5):620-626. PubMed ID: 33734927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study.
    Ploussard G; Staerman F; Pierrevelcin J; Larue S; Villers A; Ouzzane A; Bastide C; Gaschignard N; Buge F; Pfister C; Bonniol R; Rebillard X; Fadli S; Mottet N; Saint F; Saad R; Beauval JB; Roupret M; Audenet F; Peyromaure M; Delongchamps NB; Vincendeau S; Fardoun T; Rigaud J; Soulie M; Salomon L;
    World J Urol; 2014 Oct; 32(5):1331-8. PubMed ID: 24270970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macroscopic locoregional relapse from prostate cancer: which role for salvage radiotherapy?
    Bruni A; Ingrosso G; Trippa F; Di Staso M; Lanfranchi B; Rubino L; Parente S; Frassinelli L; Maranzano E; Santoni R; Sighinolfi MC; Lohr F; Mazzeo E
    Clin Transl Oncol; 2019 Nov; 21(11):1532-1537. PubMed ID: 30868389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow-up comparing salvage radiation therapy and androgen-deprivation therapy for biochemical recurrence after radical prostatectomy.
    Matsumoto K; Niwa N; Hagiwara M; Kosaka T; Takeda T; Yasumizu Y; Tanaka N; Morita S; Mizuno R; Shinojima T; Hara S; Asanuma H; Oya M
    Int J Clin Oncol; 2021 Apr; 26(4):744-752. PubMed ID: 33387085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of salvage radiotherapy initiation at PSA ≤ 0.5 ng/ml on metastasis-free survival in patients with relapsed prostate cancer following prostatectomy.
    Lee EE; Singh T; Hu C; Han M; Deville CJ; Halthore A; Greco S; Tran P; DeWeese T; Song DY
    Prostate; 2023 Feb; 83(2):190-197. PubMed ID: 36316967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Salvage radiotherapy for biochemical recurrence after radical prostatectomy: does the outcome depend on the prostate cancer characteristics?
    Viani GA; Hamamura AC; Correa AC; de Arruda FT
    Int Braz J Urol; 2019; 45(2):237-245. PubMed ID: 30676298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy.
    Kim D; Kim DY; Kim JS; Hong SK; Byun SS; Lee SE
    PLoS One; 2021; 16(9):e0256778. PubMed ID: 34506516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Wrong to be Right: Margin Laterality is an Independent Predictor of Biochemical Failure After Radical Prostatectomy.
    Kang JJ; Reiter RE; Kummer N; DeKernion J; Steinberg ML; King CR
    Am J Clin Oncol; 2018 Jan; 41(1):1-5. PubMed ID: 26237192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy.
    Yoo S; You D; Kim YS; Hong JH; Ahn H; Kim CS
    Urol Int; 2017; 99(4):406-413. PubMed ID: 29020683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: results from the SEARCH database.
    Moreira DM; Jayachandran J; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Stephenson AJ; Freedland SJ
    BJU Int; 2009 Nov; 104(10):1452-6. PubMed ID: 19466946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utilization of Salvage Radiation Therapy for Biochemical Recurrence After Radical Prostatectomy.
    Hawken SR; Spratt DE; Qi J; Linsell SM; Cher ML; Ghani KR; Miller DC; Montie JE; Morgan TM;
    Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1030-1034. PubMed ID: 30682490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.